



RealRate

PHARMACEUTICAL 2018











RealRate

PHARMACEUTICAL 2018



Moleculin Biotech Inc. Rank 82 of 342

The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 135% points. The greatest weakness of Moleculin Biotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 180%, being 134% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	8,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,215
Liabilities, Non-Current	0
Other Assets	11,148
Other Compr. Net Income	0
Other Expenses	2,566
Other Liabilities	150
Other Net Income	1,387
Other Revenues	9.0
Property and Equipment	33
Research and Development	4,545
Selling, General and Administrative Expense	4,090

Output Variable	Value in 1000 USD
Assets	19,483
Liabilities	2,365
Expenses	11,201
Revenues	9.0
Stockholders Equity	17,118
Net Income	-9,805
Comprehensive Net Income	-9,805
Economic Capital Ratio	180%

